Outcomes of sacral neuromodulation for chronic pelvic pain: a Finnish national multicenter study.


Journal

Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614

Informations de publication

Date de publication:
03 2020
Historique:
received: 30 07 2019
accepted: 06 01 2020
pubmed: 23 1 2020
medline: 28 4 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

The aim of this study was to report the outcomes of sacral neuromodulation (SNM) in chronic pelvic pain (CPP) patients in the Finnish national cohort. This was a register-based retrospective study, involving all the centers that provide SNM treatment in Finland. The data of all patients treated with SNM for CPP were gathered from Oulu-, Turku-, Tampere- and Helsinki University Hospitals, as well as Jyväskylä and Seinäjoki Central Hospitals. All patients who had been tested for SNM implantation prior to April 2017 were included in the study. A total of 51 patients were selected for SNM treatment due to CPP from 2004 until 2017. The mean follow-up time was 13.8 months (SD 22.9 months). A total of 28 patients (57%) advanced from testing to permanent stimulator implantation. There were 21 patients (41%) who had a working modulator implanted at the end of follow-up. Patients with endometriosis-related pain had a significantly higher permanent implantation rate than the overall implantation rate (88% vs. 57%; p = 0.01). The endometriosis patients also had a higher overall success rate by the end of the follow-up (75% vs. 41%; p = 0.026) CONCLUSIONS: SNM may be a viable treatment option for patients with CPP due to endometriosis. Further research on SNM treatment for endometriosis patients with refractory CPP is needed.

Sections du résumé

BACKGROUND
The aim of this study was to report the outcomes of sacral neuromodulation (SNM) in chronic pelvic pain (CPP) patients in the Finnish national cohort.
METHODS
This was a register-based retrospective study, involving all the centers that provide SNM treatment in Finland. The data of all patients treated with SNM for CPP were gathered from Oulu-, Turku-, Tampere- and Helsinki University Hospitals, as well as Jyväskylä and Seinäjoki Central Hospitals. All patients who had been tested for SNM implantation prior to April 2017 were included in the study.
RESULTS
A total of 51 patients were selected for SNM treatment due to CPP from 2004 until 2017. The mean follow-up time was 13.8 months (SD 22.9 months). A total of 28 patients (57%) advanced from testing to permanent stimulator implantation. There were 21 patients (41%) who had a working modulator implanted at the end of follow-up. Patients with endometriosis-related pain had a significantly higher permanent implantation rate than the overall implantation rate (88% vs. 57%; p = 0.01). The endometriosis patients also had a higher overall success rate by the end of the follow-up (75% vs. 41%; p = 0.026) CONCLUSIONS: SNM may be a viable treatment option for patients with CPP due to endometriosis. Further research on SNM treatment for endometriosis patients with refractory CPP is needed.

Identifiants

pubmed: 31965400
doi: 10.1007/s10151-020-02148-2
pii: 10.1007/s10151-020-02148-2
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-220

Références

Neurourol Urodyn. 2008;27(8):779-81
pubmed: 18551562
Colorectal Dis. 2019 Sep;21(9):1058-1066
pubmed: 30985984
Arch Gynecol Obstet. 2016 Sep;294(3):519-23
pubmed: 26848858
Int Urogynecol J. 2019 Jul;30(7):1023-1035
pubmed: 30874835
Int J Colorectal Dis. 2012 Jul;27(7):921-6
pubmed: 22203519
Sci Rep. 2017 Sep 8;7(1):11031
pubmed: 28887515
BMC Public Health. 2006 Jul 06;6:177
pubmed: 16824213
PLoS One. 2019 Oct 10;14(10):e0223316
pubmed: 31600241
Case Rep Neurol Med. 2017;2017:2197831
pubmed: 28367344
Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:30-3
pubmed: 26319653
Am Fam Physician. 2006 Aug 15;74(4):594-600
pubmed: 16939179
Pain. 2009 Dec;146(3):238-44
pubmed: 19836888
J Urol. 2018 Jan;199(1):229-236
pubmed: 28709886
Health Qual Life Outcomes. 2010 Nov 24;8:138
pubmed: 21106059
J Urol. 2011 Aug;186(2):387-93
pubmed: 21683381
Obstet Gynecol Surv. 2001 Dec;56(12):757-64
pubmed: 11753178
Neurourol Urodyn. 2018 Jun;37(5):1823-1848
pubmed: 29641846
Dis Colon Rectum. 2009 Mar;52(3):456-62
pubmed: 19333046
Urology. 1982 Dec;20(6):614-9
pubmed: 7179629
Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Jun;14(3):389-402
pubmed: 10962633
Acta Obstet Gynecol Scand. 2013 Aug;92(8):881-7
pubmed: 23710833
Rev Assoc Med Bras (1992). 2010 Jul-Aug;56(4):467-71
pubmed: 20835646

Auteurs

A Zegrea (A)

Seinäjoki Central Hospital, Hanneksenrinne 7, 60220, Seinäjoki, Finland. adrian.zegrea@epshp.fi.

J Kirss (J)

Turku University Hospital, Turku, Finland.
Vaasa Central Hospital, Vaasa, Finland.

T Pinta (T)

Seinäjoki Central Hospital, Hanneksenrinne 7, 60220, Seinäjoki, Finland.

T Rautio (T)

Oulu University Hospital, Oulu, Finland.

P Varpe (P)

Turku University Hospital, Turku, Finland.

M Kairaluoma (M)

Jyväskylä Central Hospital, Jyväskylä, Finland.

M Aho (M)

Tampere University Hospital, Tampere, Finland.

C Böckelman (C)

Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

M Lavonius (M)

Turku University Hospital, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH